Immutep Limited (ASX:IMM)
0.3800
-0.0050 (-1.30%)
Feb 5, 2026, 4:10 PM AEST
Immutep Revenue
In the fiscal year ending June 30, 2025, Immutep had annual revenue of 5.04M AUD with 31.28% growth. Immutep had revenue of 1.90M in the half year ending June 30, 2025, with 4.17% growth.
Revenue
5.04M
Revenue Growth
+31.28%
P/S Ratio
111.03
Revenue / Employee
162.70K
Employees
31
Market Cap
560.01M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.04M | 1.20M | 31.28% |
| Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
| Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
| Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
| Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Neuren Pharmaceuticals | 218.86M |
| Clinuvel Pharmaceuticals | 95.02M |
| PYC Therapeutics | 23.49M |
| Clarity Pharmaceuticals | 9.46M |
| Orthocell | 7.55M |
| Racura Oncology | 6.04M |
| Starpharma Holdings | 5.85M |
| Botanix Pharmaceuticals | 5.79M |
Immutep News
- 7 days ago - Immutep Quarterly Activities Report Q2 FY26 - GlobeNewsWire
- 6 weeks ago - Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study - GlobeNewsWire
- 2 months ago - India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug - Reuters
- 2 months ago - Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa - Business Upturn
- 3 months ago - Immutep Limited (IMMP) Presents at ESMO Congress 2025 - Slideshow - Seeking Alpha
- 3 months ago - Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 - GlobeNewsWire
- 5 months ago - Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewsWire
- 6 months ago - Immutep Quarterly Activities Report Q4 FY25 - GlobeNewsWire